Clinical trials: RA - Rheumatoid Arthritis
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the direct/indirect costs of disease management in patients with refractory psoriatic arthritis…
- Trial name
- NCT00303186
- Where
- 9 sites in Italy
- Volunteers
- 107 people
- Sponsor
- Pfizer
Rheumatoid Arthritis (RA)
QLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis
The objective of this randomized, double-blind, placebo-controlled phase II clinical trial is to investigate the safety and efficacy of QLS12010 in subjects with moderate-to-severe rheumatoid arthritis.The main questions it aims…
- Trial name
- NCT07377773
- Testing
- QLS12010
- Volunteers
- 180 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis
The purpose of this study is to evaluate the efficacy and safety of infliximab (Remicade) in patients with early rheumatoid arthritis.
- Trial name
- NCT00236028
- Testing
- Infliximab
- Volunteers
- 607 people
- Sponsor
- Centocor, Inc.
Arthritis, Rheumatoid
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT00814307
- Testing
- CP-690,550
- Where
- 95 sites in United States, Brazil and 14 more
- Volunteers
- 611 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.
The purpose of this study is to assess the efficacy and safety of TAS5315 in combination with methotrexate in a 12 week or 36 week in participants with rheumatoid arthritis with inadequate response to methotrexate.
- Trial name
- NCT03605251
- Testing
- TAS5315 low dose, TAS5315 high dose
- Where
- Japan
- Volunteers
- 91 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Healthy, Rheumatoid Arthritis
Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled study designed in 3 parts to assess the safety, tolerability, and PK of single and multiple ascending doses of FPA008 in adult healthy volunteers (Parts 1 and 2) and…
- Trial name
- NCT01962337
- Testing
- FPA008
- Where
- 6 sites in Hungary, Netherlands and 1 more
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Five Prime Therapeutics, Inc.
Rheumatoid Arthritis
Methotrexate-Inadequate Response Autoinjector Device Sub Study
The purpose of this study is to implement a substudy in approximately 120 rheumatoid arthritis (RA) subjects to compare the steady-state serum trough concentration (Cminss), Cmax and area under the curve (AUC) during the dosing…
- Trial name
- MTX-IR (NCT01844895)
- Testing
- Abatacept
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Rheumatoid
Assessment of the Disease Severity and Treatment Patterns of Rheumatoid Arthritis in Eastern Europe, Middle East and North African Countries (P08167)
The study will assess the disease severity and treatment patterns of rheumatoid arthritis in Eastern European, Middle Eastern, and North African countries.
- Trial name
- NCT01313871
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Korean Post-marketing Surveillance for Orencia®
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Orencia® so that the regulatory…
- Trial name
- NCT01583244
- Testing
- No Intervention (subjects were previously treated with Orencia®)
- Where
- South Korea
- Volunteers
- 701 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis, Ankylosing Spondylarthritis
Yuflyma® (Adalimumab), Patient Experience After Switching
Patient preference and experience can impact patients' adherence and persistence regarding a treatment, especially when switching.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- YU-MATTER (NCT05427942)
- Testing
- Adalimumab
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Celltrion HealthCare France
Arthritis, Rheumatoid
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis.
- Trial name
- NCT00042068
- Testing
- Meloxicam
- Where
- 153 sites in United States, Argentina and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis
The purpose of this study was to collect data on the incidence of adverse drug reactions, infections and malignant tumors, as well as factors that might affect the safety and effectiveness of Humira® (adalimumab; 40mg/0.8 mL) in…
- Trial name
- NCT01163318
- Volunteers
- 552 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA
In Israel, data is lacking regarding the long-term effectiveness of Adalimumab in outpatient real life setting. Moreover, the association between long-term effectiveness of Adalimumab and patients' functional status as well as…
- Trial name
- ORIENT (NCT02322723)
- Sponsor
- AbbVie
Arthritis, Rheumatoid
Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA
The primary purpose of this study is to evaluate the safety and efficacy of a once-weekly dose of etanercept for rheumatoid arthritis. Currently, patients in Japan can only use 25 mg etanercept two times a week.
- Trial name
- NCT00418717
- Testing
- etanercept
- Where
- 12 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00603525
- Testing
- Ofatumumab
- Where
- 60 sites in Argentina, Denmark and 10 more
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
The primary objectives of this study is to explore the efficacy of mavrilimumab compared with golimumab in the treatment of adult subjects 18-80 years of age with moderate-to-severe active rheumatoid arthritis (RA) who have an…
- Trial name
- NCT01715896
- Testing
- Golimumab 50 mg, Mavrilimumab 100 mg
- Where
- 39 sites in Argentina, Colombia and 12 more
- Volunteers
- 215 people
- Sponsor
- MedImmune LLC
Rheumatoid Arthritis
A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
This study will evaluate the efficacy and safety of various treatment and retreatment regimens of MabThera. All patients will receive concomitant methotrexate, 10-25mg once weekly either orally or parenterally.
- Trial name
- NCT00422383
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 91 sites in Australia, Belgium and 16 more
- Volunteers
- 378 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate
PLX3397 is a selective inhibitor of Fms and Kit activity. The objective of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) of orally administered PLX3397 during…
- Trial name
- NCT01090570
- Testing
- PLX3397
- Where
- 5 sites in United States
- Sponsor
- Plexxikon
Rheumatoid Arthritis
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT01373151
- Testing
- BMS-945429, Methotrexate
- Where
- 100 sites in United States, Argentina and 17 more
- Volunteers
- 418 people
- Sponsor
- CSL Behring
Rheumatoid Arthritis
Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers
The purpose of this study was to compare the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ. after subcutaneous injection in healthy male volunteers.
- Trial name
- NCT01635686
- Testing
- DWP422 25mg, ENBREL 25MG PFS INJ.
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.